Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Partner Organizations

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Blog | December 06, 2022

UP & UPC Chronology

Article | November 18, 2022

Principal Michael Shepherd Authors Law360 Expert Analysis, "Why PTAB 'Step 2B' Reversal Rates Are Falling"

Blog | November 01, 2022

ITC Monthly Wrap-Up: October 2022

Blog | November 01, 2022

Limelight v. Akamai: A software case worthy of biotech's attention

Article | October 20, 2022

Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care

Article | October 12, 2022

Principals Matt Colvin and Betsy Flanagan Author IAM Article "Five Tips to Create a Battle-Ready Portfolio From the Get-Go"

Blog | October 11, 2022

Federal Circuit Affirms PTAB's Final Written Decision that Merck's Claimed Inventions Were Not "At Once Envisaged" From the Prior Art

Blog | October 11, 2022

Legal Alert: Unitary Patent and UPC Start Date Target Is Now 1 April 2023

Article | October 05, 2022

Supplemental Examination

Article | October 05, 2022

Ex Parte Reexamination

Article | October 05, 2022

Post-Grant Review

Article | October 05, 2022

Covered Business Method Review